Loading...
•
Sep 30, 2024
DexCom Q3 2024 Earnings Report
Dexcom's third quarter results were in line with expectations, driven by improved execution and strategic product launches.
Key Takeaways
Dexcom's Q3 2024 revenue grew by 2% year-over-year to $994.2 million. The company launched Stelo, a new biosensor for adults with prediabetes and type 2 diabetes, and advanced its international product portfolio with Dexcom G7 and Dexcom ONE+ launches. The company is reiterating its fiscal year 2024 revenue guidance of approximately $4.00 - 4.05 billion.
Revenue grew 2% year-over-year to $994.2 million.
U.S. revenue declined 2%, while international revenue grew 12%.
Launched Stelo, the first over-the-counter glucose biosensor in the U.S.
Advanced international product portfolio with launches of Dexcom G7 in Australia and Dexcom ONE+ in France.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Dexcom is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:
Positive Outlook
- Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth)
- Non-GAAP Gross Profit Margin of approximately 63%
- Non-GAAP Operating Margin of approximately 20%
- Adjusted EBITDA Margin of approximately 29%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...